Recent Headlines
Synpromics Announces Highly Successful Results from Plant Science Projects
Synpromics Limited, a privately held, Scottish-based synthetic biology company today announced that it has successfully generated several highly effective synthetic promoters for use in plants. - August 22, 2014 - Synpromics Ltd
Cheers—Creative Biomart Launches High-Throughput Protein Production
The marketing chief staff of Creative Biomart has announced today that they will release the high-throughput protein production service on this very day in the aim of helping speed up their customer’s protein production project. Protein expression is widely used in the production of... - August 22, 2014 - Creative Biomart
Creative Biomart Signed Industrial Enzymes Agreement
Creative Biomart signed an Industrial Enzymes Agreement with a UK Industrial giant (the name of the company is not allowed to be exposed according to the agreement). On the basis of this agreement, Creative Biomart is going to provide High-temperature Alpha-amylase for beer, Mid-temperature... - August 20, 2014 - Creative Biomart
MMS Holdings and Oncology Trials Insights Form Strategic Partnership to Deliver Comprehensive Oncology Support Services
MMS Holdings Inc., a global clinical research organization that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries, and Oncology Trials Insights (OTI), an organization of oncology key opinion leaders that architect superior clinical trial... - August 18, 2014 - MMS Holdings Inc.
Polmacoxib Demonstrates Prevention and Treatment Effects in Colorectal Cancer
CrystalGenomics, Inc., a clinical stage biopharmaceutical company headquartered in Korea, has reported a positive outcome from an investigational preclinical research conducted, in part, at the University of Texas MD Anderson Cancer Center by Dr. Raymond N. DuBois’ laboratory where the... - August 15, 2014 - CrystalGenomics, Inc.
Creative Diagnostics Expands Its Antibody Pairs Offering
By the time of the release, Creative Diagnostics has expanded its antibody pairs to over 40,000. - August 14, 2014 - Creative Diagnostics
Creative Diagnostics Expands Database of Antibody Pairs
The expanding of Creative Diagnostics' database of antibody pairs could largely save the preparation time of investigators. - August 01, 2014 - Creative Diagnostics
CHI Announces Its 2nd Annual FAST: Functional Analysis & Screening Technologies Congress, November 17-19, 2014, Boston, MA
Keynote Presentations Delivered by George Church, Anna Collén, Meir Click and More - July 29, 2014 - Cambridge Healthtech Institute
MoBiTec, Germany, Announces Availability of Human Herpesvirus-6 (HHV-6) Assay Kits
Human herpesvirus (HHV-) 6 has been associated with various neurological diseases, including encephalitis, meningitis, epilepsy, and multiple sclerosis. MoBiTec partners with VIDIA, Czech Republic, to offer HHV-6 assay kits worldwide. - July 25, 2014 - MoBiTec GmbH
Creative Diagnostics Announces New Big Promotion Activity for Antibodies
Creative Diagnostics's July Big Promotion is open to customers around the world. - July 22, 2014 - Creative Diagnostics
MoBiTec GmbH Teams Up with Protobios to Offer Epitope Mapping Service Using Mimotope Variation Analysis (MVA) Technology
MoBiTec, Germany, partners with the Estonian biotechnology company Protobios to offer Mimotope Variation Analysis (MVA)-based antibody epitope mapping service to scientists worldwide. - July 19, 2014 - MoBiTec GmbH
Case Study: Stem Cells vs Coronary Artery Bypass Surgery in a Patient with Multi-Vessel Disease 6 Year Follow Up
Stem cells outperform heart bypass surgery. A heart patient treated with his own stem cells instead of undergoing coronary bypass surgery is exceeding all expectations 6 years after his adult stem cell treatment. - July 17, 2014 - Regenocyte Worldwide
Hormel Foods Specialty Products Division and VIRUN®, Granted Patent No. 8,741,373
VIRUN® and the Specialty Products Division at Hormel Foods were granted Patent number 8,741,373, Composition for Non-Polar Compounds. This particular patent allows unwavering high oil load encapsulation of non-polar compounds, such as Omega-3 EPA and DHA, CoQ10, Vitamins A, D, E, K, Carotenoids such as Lutein, Beta Carotene or Astaxanthin into certain water soluble and stable foods and beverages. - July 09, 2014 - VIRUN
Recursion Pharmaceuticals Announces Funding for Rett Syndrome Research
Recursion Pharmaceuticals has received support for focused work to identify a treatment for Rett Syndrome by the Rett Syndrome Research Trust. Recursion will apply its innovative drug discovery platform immediately to investigate the gene MECP2 in an effort to identify new therapeutics for the condition. - July 09, 2014 - Recursion Pharmaceuticals
Mirus Reagent Agent® Now on MoBiTec Website - Find the Appropriate Transfection Reagent for Your Cell Line and Experiment
MoBiTec GmbH, Germany, together with the transfection experts of Mirus Bio, USA, brings you the Reagent Agent® - a tool designed to determine the best solution for delivery of any nucleic acids into any cell type, including hard-to-transfect cell lines and primary cells. - July 05, 2014 - MoBiTec GmbH
CrystalGenomics Receives KRW 13 Billion in Strategic Investment from the Global Pharmaceutical Industry Development Fund
CrystalGenomics, Inc., a late clinical stage biopharmaceutical company focused on developing and commercializing novel drugs for therapeutic areas of unmet medical needs, has just announced that it has received KRW 13 billion (USD 12.8 Million) from the Global Pharmaceutical Industry Development... - June 27, 2014 - CrystalGenomics, Inc.
AveXis Announces Dosing of First Patient for Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 at Nationwide Children’s Hospital
AveXis, Inc., a synthetic biology platform company, today announced that the first patient in the Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 has now been enrolled and dosed by Nationwide Children’s Hospital. This trial utilizes chariSMA, the gene therapy product developed... - June 26, 2014 - AveXis Inc.
iPathwayGuide Now Available in Illumina’s BaseSpace Apps
Advaita Bioinformatics today announced the addition of its iPathwayGuide application to BaseSpace Apps, Illumina’s applications store and informatics community dedicated to advancing genomic analysis. iPathwayGuide is a web based pathway analysis tool that goes beyond the typical statistical... - June 25, 2014 - Advaita Corporation
Arbovax Closing in on Vaccine for Chikungunya
Arbovax, Inc., a clinical stage biotechnology company, has successfully demonstrated in an animal model the efficacy of its vaccine technology for the treatment of Chikungunya, a mosquito borne virus that has recently emerged in the US. “There was a major outbreak in the Caribbean that... - June 21, 2014 - Arbovax Inc
AveXis to Present at Piper Jaffray GenomeRX Symposium
AveXis, a clinical stage synthetic biology platform company, today announced that Mr. John Carbona, Chief Executive Officer and other members of the AveXis team will participate in the panel discussion “The Power Alley: Gene Therapy For Neuromuscular Disorders” at the Piper Jaffray... - June 20, 2014 - AveXis Inc.
Second Annual Eclipse IP Futures Conference Delivers Real World Insights on Monetizing Intellectual Property
Patent Value, America Invents Act, and “Patent Trolls” Big Part of Conversation at Event Hosted by RTI International, Neopatents, NC COIN - June 20, 2014 - COIN
MoBiTec GmbH, Germany, and Invent Biotechnologies Inc., USA, Sign Distribution Agreement for the European Market
MoBiTec GmbH, Germany, focused on selling products for life science research, has entered into a distribution agreement with Invent Biotechnologies, Inc., USA. Together with Invent Biotechnologies, MoBiTec expands its portfolio of premier brands. - June 19, 2014 - MoBiTec GmbH
VIRUN® & Pacific Deep Ocean Biotech Combine Natural Mineral Complexes with OmegaH2O® EPA and DHA for Foods, Beverages & Supplements
Virun, and Pacific Deep Ocean Biotech (PDOB), work together to provide mineral complexes that are derived from the ocean with Omega-3 EPA and DHA that deliver clean label claim and eco-friendly sustainable solutions. The combination allows a source for mineral complexes in VIRUN’s patent and patents-pending technologies that naturally yield low metal content to avoid reactivity with omega-3 EPA and DHA, all-the-while delivering a consistent level of Calcium, Sodium, Potassium and Magnesium. - June 18, 2014 - VIRUN
NC COIN, Shanahan Law Group, NC Biotechnology Center Announce Start Up and Early Stage Legal Series
Informative Five-Week seminar Series to Cover Topics from Business Formation, to Fund Raising and Exits, to IP Issues to International Business Transactions - June 14, 2014 - COIN
MoBiTec Launches SpeedBlot (His) – A Strikingly Fast and Easy-To-Use Western Blot Stain for His-Tagged Proteins
Instant detection of poly-histidine tagged proteins on nitrocellulose membrane with SpeedBlot (His) is easy and does not require relevant hands-on time. Even 0.1 pmol detection limits can be achieved with this highly sensitive detection reagent. While common Western Blot protocols require 6 to 21 hours, staining with SpeedBlot (His) is completed after just about 90 minutes. - June 12, 2014 - MoBiTec GmbH
Discover the Next IDE Inhibitor with the Newly Launched SensoLyte® IDE Activity Assay
AnaSpec Launches Industry’s First FRET-based Assay for Measurement of Insulin Degrading Enzyme (IDE) Activity for inhibitor high throughput screening- the SensoLyte® 520 IDE Activity Assay Kit. - June 12, 2014 - AnaSpec, EGT Group
Women’s Health: Dr. Kathy Maupin Announces a Free Webinar to Answer Questions About Hormone Replacement
Hormone expert will answer questions about treatment for symptoms of menopause and testosterone deficiency through bioidentical hormone replacement therapy. - June 08, 2014 - BioBalance Health
AveXis to Present at Families of Spinal Muscular Atrophy Annual Conference
AveXis, a clinical stage synthetic biology platform company, today announced that Dr. Allan Kaspar, Chief Scientific Officer, will be presenting at The Family and Researcher Poster Session at The Annual Spinal Muscular Atrophy Conference, which will be held on Thursday, June 12, 2014 in National... - June 08, 2014 - AveXis Inc.
Recursion Pharmaceuticals Announces Dr. H. Perry Fell as the First Member of Business Advisory Panel
Recursion Pharmaceuticals, a biotech start-up in Salt Lake City today announced the formation of its Business Advisory Panel. The first appointment to the Advisory Panel is H. Perry Fell, MBA, Ph.D. Perry is a distinguished scientist and leader who most prominently co-founded Seattle Genetics (NASDAQ: SGEN) and served as its CEO from start-up through IPO. - June 05, 2014 - Recursion Pharmaceuticals
ACT Enters Phase I Human Clinical Trials with First-in-Class Anti-Cancer Drug Candidate
Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, announced today that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in... - June 04, 2014 - Advanced Cancer Therapeutics
Industry's First Fluorimetric Assay for Glutaminyl Cyclase
AnaSpec Launches Industry’s First Fluorimetric, 96-well format Assay for Measurement of Glutaminyl Cyclase (QC) Activity - the SensoLyte® Green Glutaminyl Cyclase Activity Assay Kit. - May 29, 2014 - AnaSpec, EGT Group
Life Science Strategy Group Launches the OutsourcePharma Advisory Board
Online community dedicated to pharmaceutical sponsors provides open forum to discuss drug development and outsourced Contract Research Organization (CRO) services. - May 28, 2014 - Life Science Strategy Group, LLC
MiTeGen Awarded $998K NIH Phase II SBIR Grant to Develop Hyperquenching Devices
Two year funding for the development of advanced cooling devices. - May 24, 2014 - MiTeGen, LLC
Northeastern M.D.s to Gather for Presentation by Dr. Emil J. Haldey, Leading Pharmaceutical Compounding Expert
The prestigious National Medical Association will host a seminar on Friday featuring Dr. Emil J. Haldey, a doctor of pharmacy and a leader in the specialized field of pharmaceutical compounding. The event will take place May 23, beginning at 2 p.m., during the National Medical Association Annual... - May 22, 2014 - HALDEY Pharmaceutical Compounding
AveXis Announces Opening of Enrollment for Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 at Nationwide Children's Hospital
AveXis, Inc., a clinic-ready synthetic biology platform company, today announced that the Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 has now formally begun enrollment at Nationwide Children’s Hospital. This trial will utilize chariSMA, the gene therapy product developed... - May 16, 2014 - AveXis Inc.
MiTeGen Announces Collaboration and License Agreements with MagnebotiX and NatX-ray
MiTeGen LLC, a provider of innovative consumables for X-ray diffraction, crystallography and protein crystallization to academic, pharmaceutical, industrial and government researchers around the world, announced that it has signed agreements with MagnebotiX AG, and with NatX-ray SAS, and NatX-ray LLC for the development and distribution of RodBot non-contact magnetic rolling sample manipulation technology for crystallization and crystal handling. - May 14, 2014 - MiTeGen, LLC
VIRUN NutraBIOsciences™, Leader in Cognitive-Functional-Ingredients, to Sponsor Cognitive Health Forum at NutraIngredients-USA
VIRUN, leader in Cognitive health ingredients, is sponsoring NutraIngreidents Cognitive Health Forum on May 22nd, 2014. According to NutraIngredients-USA, “Industry leaders from companies such as Abbott Nutrition, Standard Process, Nawgan, and Euromonitor will join for a discussion of the cognitive health sector, from science and claim substantiation, to market sizing and key consumer demographics.” - May 13, 2014 - VIRUN
MoBiTec GmbH to Attend the International Conference on Stem Cell and Tissue Formation in Dresden, Germany, from July 8-11, 2014
For the 5th time, Stem Cell researchers will convene for the International Conference on Stem Cell and Tissue Formation in Dresden, Germany. At MoBiTec's booth high quality products as well as cutting-edge technologies will be presented. - May 09, 2014 - MoBiTec GmbH
Xcelthera Secures Patent for Large-Scale Production High Quality Human ES Cell Therapy Products
Xcelthera Inc and its joint research partner San Diego Regenerative Medicine Institute announced today that the USPTO has granted Patent No. 8,716,017 entitled “Technologies, Methods, and Products of Small Molecule-Directed Tissue and Organ Regeneration from Human Pluripotent Stem Cells”. - May 08, 2014 - Xcelthera Inc
MoBiTec GmbH, Germany, Issues New Fluorescent Probes Brochure, Ready for Free Download as PDF
A brochure featuring Fluorescent Probes for Protein and Nucleic Acid Labeling provided by MoBiTec as Free PDF Download. - May 08, 2014 - MoBiTec GmbH
Solanbridge Group Inc. Announces Appointment of Dr. Mark T. Cullen
Solanbridge Group (SLNX) has hired Dr. Mark Cullen to develop CBD-enfused products for the State of Nevada. - May 02, 2014 - Solanbridge Group Inc
BiologicsCorp Launches Supernatant Protein Expression Service
BiologicsCorp proudly launches this new service - another first in the industry. They have tested many variables, including codon optimization, strain, charperones and foldases, and others. Give Supernatant Service a try, especially if your protein of interest could not be expressed in soluble form. BiologicsCorp is confident and can guarantee success - no soluble fraction for target protein, no payment for expression service. - April 25, 2014 - BiologicsCorp
AveXis Closes a Round of Financing from PBM Capital to Advance Its SMA Gene Therapy Program
AveXis, Inc., a clinic-ready synthetic biology platform company, today announced it has completed a financing round led by PBM Capital Group. This round of financing will help support the company’s gene therapy program targeting spinal muscular atrophy (SMA). AveXis’ gene therapy... - April 23, 2014 - AveXis Inc.
Women Found to be at Greater Risk for Alzheimer’s - Find Solution with MentScan from MMT
Women with Alzheimer’s Gene fight back with MMT’s screening test called the MentScan. - April 18, 2014 - MD Stem Cells
MD Stem Cells Names Top 7 Recent Stem Cell Advances
7 key advances in Stem Cell treatments and research identified by MD Stem Cells. - April 17, 2014 - MD Stem Cells
Recursion Pharmaceuticals Announces Formation of Its Scientific and Technical Advisory Board
Recursion Pharmaceuticals is a start-up biotech firm in Salt Lake City with a goal of discovering new therapeutics for the treatment of rare genetic diseases. Recursion announced the formation of its Scientific and Technical Advisory Board today, along with the appointment of Dr. Anne Carpenter and Dr. Kirk Thomas as its first two members. - April 12, 2014 - Recursion Pharmaceuticals
Dr. Kristy Ainslie Strengthens Drug Delivery Focus as She Becomes Advisor to Peptineo
Peptineo is pleased to welcome Dr. Ainslie to advisory board at Peptineo. Dr. Ainslie received her PhD in Chemical Engineering from Penn State, and after a short post doc in a start up company focused on biosensor development, Protiveris, she completed a post doc at UCSF. During her post doc, she... - April 08, 2014 - Peptineo
Dr. Applegate to Join Advisory Board at Peptineo
Peptineo is pleased to welcome Dr. Robert Applegate to the advisory board of Peptineo. Dr. Applegate is a recognized expert in microfluidics, biomedical devices and optical technologies. As a result of his research, Dr. Applegate holds patents in optical trapping, cell diagnostics and sorting, and... - April 07, 2014 - Peptineo
Peptineo, a Biotechnology Company Focused on Value Recovery in Pharma, Announces the Appointment of Kamal Garcha PhD., to Advisory Board
"We welcome the addition of Dr. Garcha," noted Sheldon K. Jordan, PhD, CEO. Dr. Garcha holds an Honor’s BSC in Cell Biology and MSc. in Zoology from Western University, and a PhD. in Cellular & Physiological Sciences from the University of British Columbia. During the course of... - April 02, 2014 - Peptineo
OsoBio Appoints Catherine Buck Director of Manufacturing
Buck has 20-plus years of experience managing pharma and commercial manufacturing plants. - April 02, 2014 - OSO BioPharmaceuticals Manufacturing, LLC